1
|
Liu S, Semenciw R, Ugnat AM and Mao Y:
Increasing thyroid cancer incidence in Canada, 1970–1996: time
trends and age-period-cohort effects. Br J Cancer. 85:1335–1339.
2001. View Article : Google Scholar : PubMed/NCBI
|
2
|
Homayouni M, Mohammad Arabzadeh SA, Nili
F, Razi F and Amoli MM: Evaluation of the presence of Epstein-Barr
virus (EBV) in Iranian patients with thyroid papillary carcinoma.
Pathol Res Pract. 213:854–856. 2017. View Article : Google Scholar : PubMed/NCBI
|
3
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM and
Schlumberger M: 2015 American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American thyroid association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Lieber MR, Ma Y, Pannicke U and Schwarz K:
The mechanism of vertebrate nonhomologous DNA end joining and its
role in V(D)J recombination. DNA Repair (Amst). 3:817–826. 2004.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Bertinato J, Tomlinson JJ, Schild-Poulter
C and Hache RJ: Evidence implicating Ku antigen as a structural
factor in RNA polymerase II-mediated transcription. Gene.
302:53–64. 2003. View Article : Google Scholar : PubMed/NCBI
|
6
|
Gullo C, Au M, Feng G and Teoh G: The
biology of Ku and its potential oncogenic role in cancer. Biochim
Biophys Acta. 1765:223–234. 2006.PubMed/NCBI
|
7
|
Capes-Davis A, Reid YA, Kline MC, Storts
DR, Strauss E, Dirks WG, Drexler HG, MacLeod RA, Sykes G, Kohara A,
et al: Match criteria for human cell line authentication: Where do
we draw the line? Int J Cancer. 132:2510–2519. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Cui H, Lan X, Lu S, Zhang F and Zhang W:
Bioinformatic prediction and functional characterization of human
KIAA0100 gene. J Pharm Anal. 7:10–18. 2017. View Article : Google Scholar : PubMed/NCBI
|
9
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Gomes BC, Silva SN, Azevedo AP, Manita I,
Gil OM, Ferreira TC, Limbert E, Rueff J and Gaspar JF: The role of
common variants of non-homologous end-joining repair genes XRCC4,
LIG4 and Ku80 in thyroid cancer risk. Oncol Rep. 24:1079–1085.
2010.PubMed/NCBI
|
11
|
Neely RJ, Brose MS, Gray CM, McCorkell KA,
Leibowitz JM, Ma C, Rothstein JL and May MJ: The RET/PTC3 oncogene
activates classical NF-κB by stabilizing NIK. Oncogene. 30:87–96.
2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Lim JW, Kim H and Kim KH: Expression of
Ku70 and Ku80 mediated by NF-kappa B and cyclooxygenase-2 is
related to proliferation of human gastric cancer cells. J Biol
Chem. 277:46093–46100. 2002. View Article : Google Scholar : PubMed/NCBI
|
13
|
Erdogdu IH, Yumrutas O, Ozgur Cevik M,
Bozgeyik I, Erdogdu M, Inan HM and Bagis H: Differential expression
of PIWIL2 in papillary thyroid cancers. Gene. 649:8–13. 2018.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Stewart BW and Kleihues P: World Cancer
ReportIARC Press; Lyon: 2003
|
15
|
Williams D: Radiation carcinogenesis:
Lessons from Chernobyl. Oncogene. 27 (Suppl 2):S9–S18. 2008.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Dobbs TA, Tainer JA and Lees-Miller SP: A
structural model for regulation of NHEJ by DNA-PKcs
autophosphorylation. DNA Repair (Amst). 9:1307–1314. 2010.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Tuteja R and Tuteja N: Ku autoantigen: A
multifunctional DNA-binding protein. Crit Rev Biochem Mol Biol.
35:1–33. 2000. View Article : Google Scholar : PubMed/NCBI
|
18
|
Liu S, Zhang B, Zhao Y, Chen P, Ji M, Hou
P and Shi B: Association of BRAFV600E mutation with
clinicopathological features of papillary thyroid carcinoma: A
study on a Chinese population. Int J Clin Exp Pathol. 7:6922–6928.
2014.PubMed/NCBI
|
19
|
Ishizaka Y, Itoh F, Tahira T, Ikeda I,
Sugimura T, Tucker J, Fertitta A, Carrano AV and Nagao M: Human ret
proto-oncogene mapped to chromosome 10q11.2. Oncogene. 4:1519–1521.
1989.PubMed/NCBI
|
20
|
Takahashi M, Ritz J and Cooper GM:
Activation of a novel human transforming gene, ret, by DNA
rearrangement. Cell. 42:581–588. 1985. View Article : Google Scholar : PubMed/NCBI
|
21
|
Nikiforov YE: RET/PTC rearrangement in
thyroid tumors. Endocr Pathol. 13:3–16. 2002. View Article : Google Scholar : PubMed/NCBI
|
22
|
Prescott JD and Zeiger MA: The RET
oncogene in papillary thyroid carcinoma. Cancer. 121:2137–2146.
2015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Thanos D and Maniatis T: NF-kappa B: A
lesson in family values. Cell. 80:529–532. 1995. View Article : Google Scholar : PubMed/NCBI
|
24
|
Amit S and Ben-Neriah Y: NF-kappaB
activation in cancer: A challenge for ubiquitination- and
proteasome-based therapeutic approach. Semin Cancer Biol. 13:15–28.
2003. View Article : Google Scholar : PubMed/NCBI
|
25
|
Aggarwal BB: Nuclear factor-kappaB: The
enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
26
|
Gupta SC, Sundaram C, Reuter S and
Aggarwal BB: Inhibiting NF-κB activation by small molecules as a
therapeutic strategy. Biochim Biophys Acta. 1799:775–787. 2010.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Uwagawa T and Yanaga K: Effect of NF-κB
inhibition on chemoresistance in biliary-pancreatic cancer. Surg
Today. 45:1481–1488. 2015. View Article : Google Scholar : PubMed/NCBI
|